137 related articles for article (PubMed ID: 9322679)
1. Expression and functional activity of P-glycoprotein in adult acute myelogenous leukemia patients.
Nuessler V; Gullis E; Pelka-Fleischer R; del Valle F; Diem H; Beyerlein S; Zwierzina H; Wilmanns W
Ann Hematol; 1997; 75(1-2):17-26. PubMed ID: 9322679
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein expression in patients with acute leukemia-clinical relevance.
Nüssler V; Pelka-Fleischer R; Zwierzina H; Nerl C; Beckert B; Gieseler F; Diem H; Ledderose G; Gullis E; Sauer H; Wilmanns W
Leukemia; 1996 Jul; 10 Suppl 3():S23-S31. PubMed ID: 8656697
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
Tsimberidou AM; Paterakis G; Androutsos G; Anagnostopoulos N; Galanopoulos A; Kalmantis T; Meletis J; Rombos Y; Sagriotis A; Symeonidis A; Tiniakou M; Zoumbos N; Yataganas X
Leuk Res; 2002 Feb; 26(2):143-54. PubMed ID: 11755464
[TBL] [Abstract][Full Text] [Related]
4. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Witz F; Rose C; Guerci O
Blood; 1995 Apr; 85(8):2147-53. PubMed ID: 7536492
[TBL] [Abstract][Full Text] [Related]
5. Anthracycline drugs and MDR expression in human leukemia.
Pogliani EM; Belotti D; Rivolta GF; Maffè PF; Corneo G
Cytotechnology; 1996; 19(3):229-35. PubMed ID: 8862011
[TBL] [Abstract][Full Text] [Related]
6. Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes--first experience with their reversal.
Nüssler V; Pelka-Fleischer R; Zwierzina H; Nerl C; Beckert B; Gullis E; Gieseler F; Bock S; Bartl R; Petrides PE
Ann Hematol; 1994; 69 Suppl 1():S25-9. PubMed ID: 7914749
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.
List AF; Spier CS; Grogan TM; Johnson C; Roe DJ; Greer JP; Wolff SN; Broxterman HJ; Scheffer GL; Scheper RJ; Dalton WS
Blood; 1996 Mar; 87(6):2464-9. PubMed ID: 8630412
[TBL] [Abstract][Full Text] [Related]
8. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.
Kasimir-Bauer S; Beelen D; Flasshove M; Noppeney R; Seeber S; Scheulen ME
Exp Hematol; 2002 Nov; 30(11):1302-8. PubMed ID: 12423683
[TBL] [Abstract][Full Text] [Related]
9. Correlation of P-glycoprotein expression and function in childhood acute leukemia: a children's cancer group study.
Ivy SP; Olshefski RS; Taylor BJ; Patel KM; Reaman GH
Blood; 1996 Jul; 88(1):309-18. PubMed ID: 8704189
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.
Benderra Z; Faussat AM; Sayada L; Perrot JY; Chaoui D; Marie JP; Legrand O
Clin Cancer Res; 2004 Dec; 10(23):7896-902. PubMed ID: 15585622
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.
Willman CL
Semin Hematol; 1997 Oct; 34(4 Suppl 5):25-33. PubMed ID: 9408958
[TBL] [Abstract][Full Text] [Related]
12. Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia.
van der Kolk DM; de Vries EG; Noordhoek L; van den Berg E; van der Pol MA; Müller M; Vellenga E
Leukemia; 2001 Oct; 15(10):1544-53. PubMed ID: 11587212
[TBL] [Abstract][Full Text] [Related]
13. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.
Ludescher C; Eisterer W; Hilbe W; Gotwald M; Hofmann J; Zabernigg A; Cianfriglia M; Thaler J
Leukemia; 1995 Feb; 9(2):350-6. PubMed ID: 7869774
[TBL] [Abstract][Full Text] [Related]
14. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar).
Advani R; Saba HI; Tallman MS; Rowe JM; Wiernik PH; Ramek J; Dugan K; Lum B; Villena J; Davis E; Paietta E; Litchman M; Sikic BI; Greenberg PL
Blood; 1999 Feb; 93(3):787-95. PubMed ID: 9920827
[TBL] [Abstract][Full Text] [Related]
15. Idarubicin monotherapy in multiply pretreated leukemia patients: response in relation to P-glycoprotein expression.
Nüssler V; Gieseler F; Zwierzina H; Gullis E; Pelka-Fleischer R; Diem H; Abenhardt W; Schmitt R; Langenmayer I; Wohlrab A; Kolb HJ; Wilmanns W
Ann Hematol; 1997 Feb; 74(2):57-64. PubMed ID: 9063374
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.
Wuchter C; Leonid K; Ruppert V; Schrappe M; Büchner T; Schoch C; Haferlach T; Harbott J; Ratei R; Dörken B; Ludwig WD
Haematologica; 2000 Jul; 85(7):711-21. PubMed ID: 10897123
[TBL] [Abstract][Full Text] [Related]
17. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
[TBL] [Abstract][Full Text] [Related]
18. Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.
Sonneveld P; Burnett A; Vossebeld P; Ben-Am M; Rosenkranz G; Pfister C; Verhoef G; Dekker A; Ossenkoppele G; Ferrant C; Yin L; Gratwohl A; Kovacsovics T; Vellenga E; Capdeville R; Löwenberg B
Hematol J; 2000; 1(6):411-21. PubMed ID: 11920222
[TBL] [Abstract][Full Text] [Related]
19. Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic leukaemia.
Higashi Y; Turzanski J; Pallis M; Russell NH
Br J Haematol; 2000 Nov; 111(2):565-9. PubMed ID: 11122104
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.
van der Kolk DM; de Vries EG; van Putten WJ; Verdonck LF; Ossenkoppele GJ; Verhoef GE; Vellenga E
Clin Cancer Res; 2000 Aug; 6(8):3205-14. PubMed ID: 10955805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]